24.12
0.54 (2.29%)
| Previous Close | 23.58 |
| Open | 23.75 |
| Volume | 165,590 |
| Avg. Volume (3M) | 370,290 |
| Market Cap | 659,918,208 |
| Price / Earnings (Forward) | 21.83 |
| Price / Sales | 7.72 |
| Price / Book | 23.94 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Profit Margin | -9.48% |
| Operating Margin (TTM) | -2.72% |
| Diluted EPS (TTM) | -0.180 |
| Quarterly Revenue Growth (YOY) | 116.90% |
| Total Debt/Equity (MRQ) | 123.34% |
| Current Ratio (MRQ) | 1.97 |
| Operating Cash Flow (TTM) | 5.53 M |
| Levered Free Cash Flow (TTM) | -14.13 M |
| Return on Assets (TTM) | -2.02% |
| Return on Equity (TTM) | -22.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Eton Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 4.39% |
| % Held by Institutions | 53.50% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cannell Capital Llc | 31 Dec 2025 | 216,917 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 37.00 (HC Wainwright & Co., 53.40%) | Buy |
| Median | 33.50 (38.89%) | |
| Low | 30.00 (Craig-Hallum, 24.38%) | Buy |
| Average | 33.50 (38.89%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 17.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 03 Mar 2026 | 30.00 (24.38%) | Buy | 17.45 |
| HC Wainwright & Co. | 02 Mar 2026 | 37.00 (53.40%) | Buy | 18.15 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RIEDEL NORBERT G | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RIEDEL NORBERT G | Director | 21 Apr 2026 | Option execute | 32,155 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |